Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
International Journal of Molecular Sciences|October 14, 2022
Antiviral Compounds Screening Targeting HBx Protein of the Hepatitis B VirusYaojia Ma, Shingo Nakamoto, Junjie Ao, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|June 1, 2022
A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosisTakafumi Sakuma, Masato Nakamura, Tetsuhiro Chiba, et al.
Biochemical and Biophysical Research Communications|March 6, 2021
Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cellsJunjie Ao, Tetsuhiro Chiba, Shuhei Shibata, et al.
International Immunopharmacology|March 31, 2023
Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinomaNa Qiang, Junjie Ao, Masato Nakamura, et al.
Journal of Cancer|April 15, 2021
Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinomaJunjie Ao, Tetsuhiro Chiba, Hiroaki Kanzaki, et al.
Scientific Reports|March 6, 2021
The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinomaHiroaki Kanzaki, Tetsuhiro Chiba, Junjie Ao, et al.
Scientific Reports|November 2, 2021
EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinomaYuko Kusakabe, Tetsuhiro Chiba, Motohiko Oshima, et al.
Anticancer Research|February 28, 2023
Successful Identification of a Novel Therapeutic Compound for Hepatocellular Carcinoma Through Screening of ADAM9 InhibitorsKeita Ogawa, Tetsuhiro Chiba, Masato Nakamura, et al.
Journal of Cancer|June 17, 2022
Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring CTNNB1 Mutation in Early Clinical ExperienceKeita Ogawa, Hiroaki Kanzaki, Tetsuhiro Chiba, et al.
Biochemical and Biophysical Research Communications|December 31, 2022
Miglustat, a glucosylceramide synthase inhibitor, mitigates liver fibrosis through TGF-β/Smad pathway suppression in hepatic stellate cellsTerunao Iwanaga, Tetsuhiro Chiba, Masato Nakamura, et al.
Pageof 5